Approvals and flops in drug development in 2023 by Giuliana Miglierini Approvals and flops in drug development in 2023 The European Medicines Agency published its annual…
The risk of a biosimilar void in Europe by Giuliana Miglierini The undergoing revision of the pharmaceutical legislation aims, among others, to redefine data protection to…